Xilio Doses First Patient in Phase 1/2 XTX501 Trial
Xilio Therapeutics dosed the first patient in a Phase 1/2 study for its PD-1 and masked IL-2 bispecific, with data expected in late 2027, highlighting further progress in its immuno-oncology pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed